UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 3)*

CAPRICOR THERAPEUTICS, INC.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

14070B 101

(CUSIP Number)

May 9, 2017

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Page 2 of 6

CUSIP No. 14070B 101

Names of Reporting Persons

Cedars-Sinai Medical Center

Check the Appropriate Box if a Member of a Group (See Instructions)

(a) ☐

(b) ☐

SEC Use Only

Citizenship or Place of Organization

California

number of shares beneficially owned by each reporting person with

Sole Voting Power

4,258,292(1)

Shared Voting Power

Sole Dispositive Power

4,258,292 (1)

Shared Dispositive Power

Aggregate Amount Beneficially Owned by Each Reporting Person

4,258,292 (1)

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

Percent of Class Represented by Amount in Row (9)

18.7%(2)

Type of Reporting Person (See Instructions)

(1) Comprised of 4,049,959 shares of the Issuer’s common stock and 208,333 shares of the Issuer’s common stock issuable upon exercise of a warrant issued to the Reporting Person on March 16, 2016 (the “Warrant”).

(2) Percentage based on 21,399,019 shares of the Issuer’s common stock outstanding as of March 14, 2017, as set forth in the Issuer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2016 and filed with the Securities and Exchange Commission on March 16, 2017, plus 1,196,291 shares of Issuer’s common stock sold in an offering by the Issuer on May 9, 2017, set forth in the Issuer’s Amendment No. 1 to Current Report on Form 8-K/A filed with the Securities and Exchange Commission on May 9, 2017, plus 208,333 shares of the Issuer’s common stock issuable upon exercise of the Warrant.

Page 3 of 6

Item 1.

(a)

Name of Issuer

Capricor Therapeutics, Inc.

(b)

Address of Issuer’s Principal Executive Offices

8840 Wilshire Blvd.

2nd Floor

Beverly Hills, CA 90211

Item 2.

(a)

Name of Person Filing

Cedars-Sinai Medical Center (the “Reporting Person”)

(b)

Address of Principal Business office or, if None, Residence

8700 Beverly Blvd.

Los Angeles, CA 90048

(c)

Citizenship

The Reporting Person is a corporation organized under the laws of the State of California.

(d)

Title of Class of Securities

Common Stock

(e)

CUSIP Number

14070B 101

Item 3.

If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a)	☐	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b)	☐	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c)	☐	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d)	☐	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);

(e)	☐	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f)	☐	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g)	☐	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h)	☐	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)	☐	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)	☐	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

(k)	☐	Group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: __________

Page 4 of 6

Item 4.

Ownership.

(a)

Amount beneficially owned: 4,258,292 (1)

(b)

Percent of class: 18.7%(2)

(c)

Number of shares as to which the person has:

(i)

Sole power to vote or to direct the vote: 4,258,292 (1)

(ii)

Shared power to vote or to direct the vote: 0

(iii)

Sole power to dispose or to direct the disposition of: 4,258,292 (1)

(iv)

Shared power to dispose or to direct the disposition of: 0

Page 5 of 6

Item 5.

Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

Item 6.

Ownership of More than Five Percent on Behalf of Another Person.

N/A

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

N/A

Item 8.

Identification and Classification of Members of the Group.

N/A

Item 9.

Notice of Dissolution of Group.

N/A

Item 10.

Certifications.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Page 6 of 6

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: May 10, 2017

	Cedars-Sinai Medical Center

	By:		/s/ James D. Laur
			Name: James D. Laur Title: Vice President for Legal & Technology Affairs